Ruixia Li Xiaofei Li He Zhou Yanting Shi Fang Wang Tong Wu Jie Liang
10.3389/fimmu.2023.1205046
Front Immunol
2023 May 23;14:1205046.
behcet’s disease case report intestinal disease tumor vedolizumab
CC BY
https://pubmed.ncbi.nlm.nih.gov/37287984/
Behcet Syndrome / complications Behcet Syndrome / diagnosis Behcet Syndrome / drug therapy Biological Products / therapeutic use Intestinal Diseases
Behcet Syndrome / complications Behcet Syndrome / diagnosis Behcet Syndrome / drug therapy Biological Products / therapeutic use Intestinal Diseases Review Case Reports Research Support, Non-U.S. Gov't Biological Factors / therapeutic use Female Humans Middle Aged Tumor Necrosis Factor Inhibitors / therapeutic use Tumor Necrosis Factor-alpha / therapeutic use Ulcer / drug therapy Ulcer / etiology vedolizumab Tumor Necrosis Factor Inhibitors Tumor Necrosis Factor-alpha Biological Factors Biological Products
PMC10242066
37287984
Successful treatment of a refractory intestinal Behcet's disease with an oncology history by Vedolizumab: a case report and literature review
2023